DIASORIN AND CARDINAL HEALTH EXTEND US DISTRIBUTION AGREEMENT THROUGH 2014

DiaSorin Group, a worldwide leader in the in-vitro diagnostic (IVD) market, today announced the renewal of a co-exclusive agreement with Cardinal Health Inc., a Fortune 19 health care services company, for the distribution of clinical laboratory instruments and immunoassay kits in the United States.

Leveraging the successful collaboration from the last several years, the agreement has been renewed for an additional three years, through the end of 2014. The initial distribution agreement between the two companies was signed in 2006.

Under the terms of the agreement, Cardinal Health will provide clinical laboratories with LIAISON® and LIAISON XL® instruments and DiaSorin immunoassay kits, recognized as best-in-class products in the market. DiaSorin will also be the exclusive supplier to Cardinal Health of Vitamin D assays distributed to the U.S. market.

The extension of the agreement highlights DiaSorin’s strategy to continue to penetrate the large U.S. IVD market through its direct sales and service structures, with support from the Cardinal Health laboratory sales force. Through this agreement, DiaSorin aims to benefit from a greater presence in the U.S. market, by combining its own capillary presence with the Cardinal Health sales network.

The U.S. market continues to represent a primary focus for DiaSorin, on the back of the excellent revenue growth achieved during the last several years through a wide offering of specialty tests in
the areas of infectious diseases and bone- and mineral-related diseases, where DiaSorin Vitamin D assays continue to play a key role as the market leader.

At the same time, Cardinal Health will expand its product offering in the market, having access to an extensive immunoassay menu, including Bone and Mineral kits, Infectious Disease kits, DiaSorin’s LIAISON® 25 OH Vitamin D Total Assay, and the newly launched LIAISON® Measles and Mumps Assays.